A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma

This trial is studying a CAR T-cell therapy called C-CAR039 (prizloncabtagene autoleucel) for patients with large B-cell lymphoma that has returned or stopped responding to treatment. CAR T-cell therapy uses your own immune cells, which are re-engineered in a lab to find and destroy cancer cells. **You may be eligible if:** - You are 18 or older - You have been diagnosed with large B-cell lymphoma (such as DLBCL, PMBCL, or transformed follicular lymphoma) confirmed by biopsy - Your cancer is CD19 or CD20 positive - Your lymphoma has relapsed or not responded after at least 2 prior treatments, or has come back after a stem cell transplant - You have at least one measurable tumor - Your organs (heart, liver, kidneys) are functioning well enough **You may NOT be eligible if:** - You have previously had an allogeneic (donor) stem cell transplant, or had an autologous transplant within the last 12 weeks - Cancer has spread to the brain or spinal cord - You have had a stroke or seizure in the past 6 months - You have an active autoimmune disease or HIV/hepatitis B/C infection - You have uncontrolled active infection Talk to your doctor to see if this trial is right for you.